Circulating biomarkers for lung cancer

Annali Italiani di Chirurgia

Volumn 70, Issue 6, 1999, Pages 831-838

  Buccheri, G ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

CEA; Follow up; Lung cancer; NSE; TPA; Tumor markers

Indexed keywords

TUMOR MARKER;

BLOOD; CANCER STAGING; CLASSIFICATION; HUMAN; LUNG TUMOR; MONITORING; PATHOLOGY; PROGNOSIS; REVIEW;

HUMANS; LUNG NEOPLASMS; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033222429     PISSN: 2239253X     EISSN: 2239253X     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Minna J.D., Higgins G.A., Glatstein E.J.: Cancer of the lung. In: De Vita V.T., Jr., Hellman S., Rosemberg S.A., editors. Cancer. Principles and practice of oncology. 2nd ed. Philadelphia: J.B. Lippincott Co, 1985, 507-597.
2. Rasmuson T., Bjork G.R., Dambe L: Tumor markers in bronchogenic carcinoma. Acta Radiol Oncol, 1983, 22:209-214.
3. Yamaguchi K., Abe K., Adachi I.: Peptide hormone production in primary lung tumors. Ree Res Cancer Res, 1985, 99:107-116.
4. Reeve J.G.: Clinical and biological relevance of lung tumour markers. Diagn Oncol, 1990, 1:305-315.
5. Ferrigno D., Buccheri G., Biggi A.: Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J, 1994, 7:186-197.
6. Niklinski J., Furman M.: Clinical tumour markers in lung cancer. Eur J Cancer Prev, 4 (in press), 1995.
7. Ferrigno D., Buccheri G.: Clinical applications of serum markers for lung cancer. Respir Med, 1995, 89:587-597.
8. Bergman B., Brezicka F.-T., Engström C.-P., Larsson S.: Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung earner. Eur J Cancer [A], 1993, 29A: 198-202.
9. Body J.J., Sculier J.P., Raymakers N., Paesmans M., Ravez P., Libert P. et al.: Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer, 1990, 65:1552-1556.
10. Buccheri G., Violante B., Sartoris A.M., Ferrigno D., Curcio A., Vola F.: Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer, 1986, 57:2389-2396.
11. Buccheri G., Ferrigno D., Sartoris A.M., Violante B., Vola F., Curcio A.: Tumor markers in bronchogenic carcinoma: superiority of tissue polyptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer, 1987, 60:42-50.
12. Buccheri G., Ferrigno D., Vola F.: Carcinoembryonic antigen (CEA), tissue polyptide antigen (TPA), and other prognostic indicators in the squamous cell carcinoma of the lung. Lung Cancer, 1993, 10:21-33.
13. Díez M., Torres A., Maestro M.L., Ortega M.D., Gomez A., Pollán M. et al.: Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer, 1996, 73:1248-1254.
14. Ferrigno D., Buccheri G.: A comprehensive evaluation of serum ferritin levels in lung cancer patients. Lung Cancer, 1992, 8:85-94.
15. Icard P., Regnarci J.-F., Essomba A., Panebianco V., Magdeleinat P., Levasseur P.: Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg, 1994, 58:811-814.
16. Jaques G., Bepler G., Holle R., Wolf M., Hannich T., Gropp C. et al.: Prognostic value of pretreatment carcinoembryonic antigen, neuron-specific enolase, and creatine kinase-BB levels in sera of patients with small cell lung cancer. Cancer, 1988, 62:125-134.
17. Järvisalo J., Hakama M., Knekt P., Srenman U.-H., Leino A., Teppo L. et al.: Serum tumor markers CEA, CA 50. TATI, and NSE in lung cancer screening. Cancer, 1993, 71:1982-1988.
18. Johnson P.W.M., Joel S.P., Love S., Butcher M., Pandian M.R., Squires L. et al.: Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer, 1993, 67:760-766.'
19. Jorgensen L.G.M., Hansen H.H., Cooper E.H.: Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in smalt cell lung cancer. Eur J Cancer Clin Oncol, 1989, 1:123-128.
20. Laberge F., Fritsche H.A., Umsawasdi T., Carr D.T., Welch S., Murphy W.K. et al.: Use of carcinoembryonic antigen in small cell lung cancer. Prognostic value and relation to the clinical course l. Cancer, 1987, 59:2047-2052.
21. Niklinski J., Furman M., Laudanski J., Kozlowski M.: Prognostic value of pretreatment CEA, SCC.-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev, 1992, 1:401-406.
22. Picardo A.I,., Torres A.J., Maestro M., Ortega D., Garcia-Asenjo J.A., Mugüerza J.M. et al.: Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non-small cell lung cancer. Cancer, 1994, 73:2305-2311.
23. Plebani M., Basso IX, Navaglia F., De Paoli M., Tommasini A., Cipriani A.: Clinical evaluation of seven tumour markers in lung cancer diagnosis: Can any combination improve the results. Br J Cancer, 1995 72:170-173.
24. Stieber P., Hasholzner U., Bodenmüller FI., Nagel D., Sunder-Plassmann L., Dienemann H. et al.: CYFRA 21-1: A new marker in lung cancer. Cancer, 1993, 72:707-713.
25. Walop W., Chrétien M., Coiman N.C., Fraser R.S., Gilbert F., Hidvegi R.S. et al.: The use of biomarkers in the prediction of survival in patients with pulmonaty carcinoma. Cancer, 1990, 65:2033-2046.
26. Buccheri G., Ferrigno D.: Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer Chest 1988 93:565-569.
27. Buccheri G., Ferrigno D.: Prognostic value of the tissue polyptide antigen in lung cancer. Chest, 1992, 101:1287-1292.
28. Buccheri G., Ferrigno D.: The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: Diagnostic yield and comparison with conventional staging methods. Chest, 1995, 107:471-476.
29. Buccheri G., Ferrigno D.: Monitoring lung cancer with tissue polyptide antigen: an ancillary, profitable serum test to evaluate treatment response andposttreatment disease status. Lung Cancer, 1995, 13:155-168.
30. Correale M., Arnberg H., Blockx P., Bombardieri E., Castelli M., Encabo G. et al.: Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. Int J Biol Markers, 1994, 9:231-238.
31. Gronowitz J.S., Bergstrom R., Nou E., Pahlman S., Brodin O., Nilsson S. et al.: Clinical and serologic markers of stage and prognosis in small cell lung cancer. Cancer, 1990, 66:722-732.
32. Mizushima Y., Hirata H., Izumi S., Hoshino K., Konishi K., Morikage T. et al.: Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay. Oncology, 1990, 47:43-48.
33. Stieber P., Dienemann H., Hasholzner U., Fabricius P.G., Schambeck C, Weinzierl M. et al.: Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers, 1994, 9:82-88.
34. Van der Gaast A., Van Putten W.L., Oosterom R., Cozijnsen M., Hoekstra R., Splinter T.A.W.: Prognostic value of serum thymidine kinase, tissue polypetide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer, 1991, 64:369-372.
35. Van der Gaast A., Kok T.C., Kbo G.S., Blijenberg B.G., Splinter T.A.W.: Disease monitoring by the tumour markers Cyfia 21.1 and TPA in patients with non-small cell lung cancer. Eur J Cancer [A],1995, 31 A: 1790-1793.
36. Bombardieri E., Seregni E., Bogni A., Ardit S., Belloli S., Busetto A. et al.: Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: Residts of a multicenter trial. Int J Biol Markers, 1994, 9:89-95.
37. Lai R.S., Hsu H.K., Lu J.Y., Ger L.P., Lai N.S.: CYFRA 21-1 enzyme-linked immunosorbent assay-Evaluation as a tumor marker in non-small cell lung cancer. Chest, 1996, 109:995-1000.
38. Muraki M., Tohda Y., Iwanaga T., Uejima H., Nagasaka Y., Nakajima S.: Assessment of serum CYFRA 21-1 in lung cancer. Cancer,1996, 77:1274-1277.
39. Niklinski J., Furman M., Chyczewska E., Chyczewski L., Rogowski F., Laudanski J.: Diagnostic and prognostic value of the new tumour marker CIFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J, 1995, 8:291-294.
40. Niklinski J., Furman M., Burzykowski T., Chyczewski L., Laudanski J., Chyczewska E. et al.: Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer. Br J Cancer, 1996, 74:956-960.
41. Pujol J.L., Grenier J., Daures J.P., Daver A., Pujol H., Michel F.B.: Serum fragment of cytocheratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res, 1993, 53:61-66.
42. Pujol J.L., Grenier J., Parrat E., Lehmann M., Lafontaine T., Quantin X. et al.: Cytokeratins as serum markers in lung cancer: A comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med, 1996, 154:725-733.
43. Rastel D., Ramaioli A., Cornillie F., Thirion B.: CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. Eur J Cancer [A], 1994, 30A:601-606.
44. Sugama Y., Kitamura S., Kawai T., Ohkubo A., Hasegawa S., Kuriyama T. et al.: Clinical usefulness of CYFRA assay in diagnosing lung cancer: Measurement of serum cytokeratin fragment. Jpn J Cancer Res, 1994, 85:1178-1184.
45. Van der Gaast A., Schoenmakers C.H.H., Kok T.C., Blijenberg B.G., Cornillie F., Splinter T.A.W.: Evaluation of a new tumour marker in patients with non-small-cell lung cancer: CIFRA 21-1. Br J Cancer, 1994, 69:525-528.
46. Wieskopf B., Demangeat C., Purohit A., Stenger R., Gries P., Kreisman H. et al.: Cyfia 21-1 as a biologic marker of non-small cell lung cancer: Evaluation of sensitivity, specificity, and prognostic role. Chest, 1995, 108:163-169.
47. Marino P., Buccheri G., Preatoni A., Ferrigno D., Luporini A.C., Pravettoni G.: Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumors. Int J Biol Markers, 1992, 7:65-67.
48. Ariyoshi Y., Kato K., Ueda R.: Biological and clinical implication of neuron-specific enolase and creatine kinase BB in small cell lung cancer. Jpn J Clin Oncol, 1986, 16:213-221.
49. Ferrigno D., Buccheri G., Cecchini C., Marchetti G.: Clinical value of a multiple biomarker assay (CEA, TPA, NSE) in patients with SCLC. GIMT, 1990, 44:135-140.
50. Harding M., McAllister J., Hulks G., Vernon D., Monie R., Paul J. et al.: Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? Br J Cancer, 1990, 61:605-607.
51. Jorgensen L.G., Osterlind K., Hansen H.H., Cooper E.H.: The prognostic influence of serum neuron specific enolase in small cell lung cancer. Br J Cancer, 1988, 58:805-807.
52. Jorgensen L.G., Hirsch F.R., Skov B.G., Osterlind K., Cooper E.H., Larsson L.I.: Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. Br J Cancer, 1991, 63:151-153.
53. Jorgensen L.G.M., Osterlind K., Hansen H.H., Cooper E.H.: Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC). Br J Cancer, 1994, 70:759-761.
54. Jorgensen L.G.M., Osterlind K., Genollá J., Gomm S.A., Hernández J.R., Johnson P.W.M. et al.: Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): A combined multivariable analysis on data from nine centres. Br J Cancer, 1996, 74:463-467.
55. Milleron B., Cadranel J., Dominique S., Rosencher L., Akoun G.: L'enolase neurono-specifique serique au cours des cancers bronchiques à petites cellules. Rev Mai Respir, 1990, 46:161-165.
56. Quoix E., Charloux A., Popin E., Pauli G.: Inability of serum neuron-specific enolase to predict disease extent in small cell lung cancer. Eur J Cancer [A], 1993, 29A:2248-2250.
57. Splinter T.A.W., Cooper E.H., Kho G.S., Osterom R., Peake M.D.: Neuron specific enolase as a guide to the treatment of small cell lung cancer. Eur J Cancer Clin Oncol, 1987, 23:171-176.
58. Szturmowicz M., Roginska E., Roszkowski K., Kwiek S., Filipecki S., Rowinska-Zakrzewska E.: Prognostic value of neuron-specif enolase in small cell lung cancer. Lung Cancer, 1993, 8:259-264.
59. Van Zandwijk N., Jassem E., Bonfrer J.M.G., Mooi W.J., Van Tinteren H.: Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol, 1992, 19 Suppl. 2:37-43.
60. Kohno N., Hamada H., Fujioka S., Hiwada K., Yamakido M., Akiyama M.: Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest, 1992, 102:1 17-122.
61. Sagman U., Feld R., Evans W.K., Wart D., Shepherd F.A., Payne D. et al.: The prognostic significance of pretreament serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol, 1991, 9:954-961.
62. Jaques G., Auerbach B., Pritsch M., Wolf M., Madry N., Havemann K.: Evaluation of serum neural cell adhesion molecule as a new tumor marker in small cell lung cancer. Cancer, 1993, 72:418-425.
63. Buccheri G., Marino P., Preatoni A., Ferrigno D., Moroni G.A.: Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumori activity? Chest, 1991, 99:1433-1437.
64. Chan C.H.S., Ho J., Lai C.K.W., Leung J.C.K., Lai K.N.: Elevated serum levels of soluble interleukin-2 receptors in lung cancer and the effect of surgery. Respiratory Medicine, 1993, 87:383-385.
65. Ginns L.C., Hoyos A.D., Brown M.C., Gaumond B.R.: Elevated concentrations of soluble interleukin-2 receptors in serum of smokers and patients with lung cancer. Ant Rev Respir Dis, 1990, 142:398-402.
66. Yamaguchi K., Nishimura Y., Kiyokawa T.: Elevated serum levels of soluble interleukin-2 receptors in small cell lung cancer. J Lab Clin Med, 1990, 116:457-461.
67. Poulakis N., Sarandakou A., Rizos D., Phocas I., Kontozoglou T., Polyzogopoulos D.: Soluble interleukin-2 receptors and other markers in primary lung cancer. Cancer, 1991, 68:1045-1049.
68. Tisi E., Lissoni P., Angeli M., Arrigoni C., Corno E., Cassina E. et al.: Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer, 1992, 69:2458-2462.
69. Takada M., Kusunoki Y., Masuda N., Matui K., Yana T., Ushijima S. et al.: Pro-gastrin-releasing peptide(31-98) as a tumour marker of small-cell lung cancer: Comparative evaluation with neuron-specific enolase. Br J Cancer, 1996, 73:1227-1232.
70. Sanchez De Cos J., Masa F., De la Cruz J.L., Disdier C., Vergara C.: Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. Chest, 1994, 105:773-776.
71. Ebert W., Leichtweis B., Bulzebruck H., Drings P.: The role of IMx SCC assays in the detection and prognosis of primary squamous-cell carcinoma of the lung. Diagn Oncol, 1992, 2:203-210.
72. Ebert W., Muley T., Drings P.: Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process. Anticancer Res, 1996, 16:2161-2168.
73. Mino N., Atsushi I., Hamamoto K.: Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. Cancer, 1988, 62:730-734.
74. Diez M., Cerdan F.J., Ortega M.D., Torres A., Picardo A., Balibrea J.L.: Evaluation of serum CA 125 as a tumor marker in non-small cell lung cancer. Cancer, 1991, 67:150-154.
75. Diez M., Torres A., Pollan M., Gomez A., Ortega D., Maestro M.L. et al.: Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer. Cancer, 1994, 73:1368-1376.
76. Kimura Y., Fujii T., Hamamoto K., Miyagawa N., Kataoka M., Iio A. et al.: Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer, 1993.
77. Molina R., Agusti C, Mañe J.M., Filella X., Jo J., Joseph J. et al.: CYFRA 21-1 in lung cancer: Comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers, 1994, 9:96-101.
78. Pujol J.-L., Cooper E.H., Lehmann M., Purves D.A., Dan-Aouta M., Midander J. et al.: Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer. Br J Cancer, 1993, 67:1423-1429.
79. Bergh J., Arnberg H., Eriksson B., Lundquist G.: The release of chromogranin A and B like activity from human lung cancer cell lines: a potential marker for a subset of small cell lung cancer. Acta Oncol, 1989, 5:651-654.
80. O'Connor D.T., Deftos L.J.: Secretion of chromogranin A a by peptide-producing endocrine neophisms. N Engl J Med, 1986, 314:1145-1151.
81. Sobol R.E., O'Connor D.T., Addison J., Suchocki K., Roiston I., Deftos L.J.: Elevated serum chromogranin A concentration in small-cell lung carcinoma. Ann Intern Med, 1986, 105:698-700.
82. Cox R., Gyde O.H., Leyland M.J.: Serum ferritin levels in small cell lung cancer. Eur J Cancer Clin Oncol, 1986, 22:831-835.
83. Muller T., Marshall R.J., Cooper E.H., Watson D.A., Walker D.A., Mearns A.J.: The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis. Eur J Cancer Clin Oncol, 1985, 21:1461-1466.
84. Gail M.H., Muenz L., Mclntire K.R.: Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer. J Natl Cancer Inst, 1986, 76:805-816.
85. Gail M.H., Muenz L., Mclntire K.R.: Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. J Natl Cancer Inst, 1988, 80:97-101.
86. Buccheri G., Ferrigno D.: Prognostic factors in lung cancer: tables and comments. Eur Respir J, 1994, 7:1350-1364.
87. Haraf D.J., Devine S., Ihde D.C., Vokes E.E.: The evolving role of systemic therapy in carcinoma of the lung. Semin Oncol, 1992 19 Suppl. 11:72-87.
88. Ihde D.C.: Drug therapy: Chemotherapy of lung cancer. N Engl J Med, 1992, 327:1434-1441.
89. Shephecrd I.A.: Current review: induction chemotherapy for locally adramed non small celi hang cancer. Ann Thorac Surg. 1993,55: 1585-1592.
90. Edelman M.J., Gandara D.R., Roach M., Benfield J.R.: Multimodality therapy in stage III non-small cell lung cancer. Ann I'horac Surg, 1996, 61:1564-1572.